Anxiety DisordersPalliative & End-of-Life DistressDepressive DisordersAyahuascaLSDDMTPsilocybin

Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying

In a large online survey of 3,192 people who had either psychedelic-occasioned or non-drug near-death/other non-ordinary experiences that changed their beliefs about death, both types produced comparable reductions in fear of death and high ratings of personal meaning and positive persisting effects, although psychedelic experiences elicited stronger mystical/near-death subjective features while non-drug events were more often rated the single most meaningful life event. Among psychedelics, ayahuasca and DMT tended to produce stronger and more positive enduring consequences than psilocybin and LSD; the authors suggest these characterisations support prospective psychedelic administration studies.

Authors

  • Roland Griffiths
  • Sandeep Nayak
  • Thomas Swift

Published

PLOS ONE
individual Study

Abstract

Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direct comparisons of these phenomena. This study directly compared psychedelic occasioned and non-drug experiences which altered individuals’ beliefs about death. Individuals who reported an experience that altered their beliefs about death occasioned by either a psychedelic drug or a near-death or other non-ordinary experience completed an online survey. Circumstances of the experience, mystical and near-death subjective features, changes in attitudes about death, and other persisting effects were evaluated. The study sample (n = 3192) included five groups: non-drug near-death or other non-ordinary experiences (n = 933), and drug experiences occasioned by lysergic acid diethylamide (LSD) (n = 904), psilocybin (n = 766), ayahuasca (n = 282), or N,N-dimethyltryptamine (DMT) (n = 307). Analyses of differences in experiences were adjusted statistically for demographic differences between groups. Compared to the psychedelic groups, the non-drug group was more likely to report being unconscious, clinically dead, and that their life was in imminent danger. The groups were remarkably similar in the reported changes in death attitudes attributed to the experience, including a reduced fear of death and high ratings of positive persisting effects and personal meaning, spiritual significance, and psychological insight. Although both psychedelic and non-drug participants showed robust increases on standardized measures of mystical and near-death experiences, these measures were significantly greater in the psychedelic participants. Non-drug participants were more likely to rate their experiences as the single most meaningful of their lives. Comparing across psychedelic substances, ayahuasca and DMT groups tended report stronger and more positive enduring consequences of the experience than the psilocybin and LSD groups, which were largely indistinguishable. These data provide a detailed characterization and comparison of psychedelic occasioned and non-drug experiences that changed attitudes about death and suggest the importance of future prospective psychedelic administration studies.

Available with Blossom Pro

Research Summary of 'Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying'

Introduction

Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) can occasion a wide range of acute subjective effects, including mystical-type experiences characterised by unity, sacredness, ineffability, and transcendence of time and space. Prior controlled research has linked drug‑occasioned mystical experiences to persistent positive changes in attitudes, mood and behaviour, and clinical trials with psilocybin have shown reductions in death anxiety among patients with life‑threatening illness. Separately, spontaneous non‑drug phenomena such as near‑death experiences (NDEs) and out‑of‑body experiences can produce similar enduring changes in attitudes about death; the Greyson Near‑Death Experience Scale was developed to quantify common phenomenological features of such events. Despite overlapping phenomenology and therapeutic interest, few studies have directly compared psychedelic‑occasioned experiences with non‑drug near‑death or other non‑ordinary experiences on common quantitative metrics. Sweeney and colleagues designed the present study to fill that gap by directly comparing people who reported a single experience that fundamentally changed their beliefs about death and dying, where the experience was either occasioned by a classic psychedelic (psilocybin, LSD, ayahuasca, or non‑ayahuasca DMT) or was a near‑death or other non‑ordinary experience occurring without psychedelic drugs. The investigation aimed to characterise contextual features of the experiences, acute phenomenology using standard instruments (for example the Mystical Experience Questionnaire and the Greyson NDE Scale), changes in death attitudes (using the Revised Death Attitude Profile, DAP‑R), and persisting personal and spiritual consequences attributed to the experience.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (27)

Papers cited by this study that are also in Blossom

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Classic hallucinogens and mystical experiences: phenomenology and neural correlates

Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects

Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)

Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)

How do psychedelics work?

Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)

Show all 27 references
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Models of psychedelic drug action: modulation of cortical-subcortical circuits

Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports

Martial, C., Cassol, H., Charland-Verville, V, Erowid, E. et al. · Consciousness and Cognition (2019)

DMT models the near-death experience

Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)

Dose-response study of N,N-dimethyltryptamine in humans: subjective effects and preliminary results of a new rating scale

Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin

MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)

350 cited

Cited By (8)

Papers in Blossom that reference this study

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)

12 cited
Intact neurophysiological markers of death denial in long-term ayahuasca users

Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)

A Transformative Trip? Experiences of Psychedelic Use

Neitzke-Spruill, L., Beit, C., Robinson, J. et al. · Neuroethics (2024)

How Do Psychedelics Reduce Fear of Death?

Letheby, C. · Neuroethics (2024)

11 cited
Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study

Nayak, S., Jackson, H., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2024)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.